Pharvaris N.V.
$28.97
▼
-3.02%
2026-04-21 08:50:01
pharvaris.com
NMS: PHVS
Explore Pharvaris N.V. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.86 B
Current Price
$28.97
52W High / Low
$29.89 / $13.6
Stock P/E
—
Book Value
$5.56
Dividend Yield
—
ROCE
-54.28%
ROE
-65.19%
Face Value
—
EPS
$-3.46
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
129
Beta
-2.58
Debt / Equity
0.29
Current Ratio
10.11
Quick Ratio
10.11
Forward P/E
-8.47
Price / Sales
—
Enterprise Value
$1.45 B
EV / EBITDA
-8.55
EV / Revenue
—
Rating
Strong Buy
Target Price
$46.62
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Syndax Pharmaceuticals, Inc. | $23.78 | — | $2.1 B | — | -66.67% | -1.62% | $25.59 / $8.58 | $0.74 |
| 2. | Moolec Science SA | $7.28 | — | $5.29 M | — | 11.2% | 344.24% | $157.05 / $3.07 | $0.7 |
| 3. | Metagenomi Therapeutics, Inc. | $1.53 | — | $55.68 M | — | -48.45% | -44.66% | $3.95 / $1.25 | $4.22 |
| 4. | Cingulate Inc. | $6.03 | — | $66.77 M | — | -418.81% | -4.51% | $11.89 / $3.2 | $0.35 |
| 5. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 6. | Innoviva, Inc. | $23.92 | 6.53 | $1.77 B | — | 10.33% | 29.09% | $25.14 / $16.52 | $15.71 |
| 7. | Denali Therapeutics Inc. | $20.54 | — | $3.26 B | — | -53.07% | -45.69% | $23.77 / $12.31 | $6.49 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -47.6 M | -39.66 M | -40.37 M | -42.19 M | -45.09 M | — |
| Net Profit | -46.74 M | -37.14 M | -45.48 M | -46.34 M | -34.76 M | — |
| EPS in Rs | -0.71 | -0.57 | -0.7 | -0.71 | -0.53 | -0.77 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -169.82 M | -145.69 M | -96.91 M | -86.71 M |
| Net Profit | -175.7 M | -134.22 M | -100.88 M | -76.33 M |
| EPS in Rs | -2.69 | -2.05 | -1.54 | -1.17 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 301.45 M | 291.37 M | 398.69 M | 167.73 M |
| Total Liabilities | 30.18 M | 23.61 M | 14.65 M | 18.47 M |
| Equity | 271.27 M | 267.76 M | 384.05 M | 149.26 M |
| Current Assets | 299.17 M | 289.42 M | 397.85 M | 166.85 M |
| Current Liabilities | 29.6 M | 22.97 M | 14.6 M | 18.22 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -137.07 M | -120.13 M | -93.05 M | -67.16 M |
| Investing CF | -0.16 M | -0.54 M | -0.09 M | -0.12 M |
| Financing CF | 160.61 M | 2.68 M | 325.39 M | 8.65 M |
| Free CF | -137.24 M | -120.67 M | -93.14 M | -67.29 M |
| Capex | -0.16 M | -0.54 M | -0.09 M | -0.12 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -33.06% | -32.15% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.